Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Core One Labs Inc C.COOL

Alternate Symbol(s):  CLABF

Healthcare Cannabis
Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.


CSE:COOL - Post by User

Core One Labs Inc
Bullboard Posts
User Avatar Image
(51)
•••
Comment by kooter33on Nov 30, 2017 12:35am
139 Views
Post# 27060766

RE:RE:RE:9 month revenues to Sept

RE:RE:RE:9 month revenues to Sept
Wisee wrote: ACB is presently trading at 54 times sales.  ($2.7B market cap / $50M in projected sales). 

Let's use a conservative 20 times sales, LDS' value will be $4.80.

Something to remember...Americans usually value at higher multiples. 
So using a sales multiple of 50 times, LDS' value will be $12.00.

Don't believe me, check out AXIM.   A couple of months ago, they reached a $1billion market cap, with zero revenues. 

LDS is going to make alot of people millionaires, hopefully it's alot of SH readers. 



The fun is just about to begin.   

Wisee



 

    


I like your numbers much more than my P/E projections. ;))
CEO's revenue projections from 2018 Sales.  https://www.youtube.com/watch?v=DHLxy4hAraA
Liking it A LOT.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities